#USA #Upsher-Smith #Vigabatrin #Maple Grove #Epilepsy Awareness

Upsher-Smith's Commitment to the Epilepsy Community

Upsher-Smith Laboratories, LLC, based in Maple Grove, Minnesota, has reaffirmed its dedication to the epilepsy community as it recognizes National Epilepsy Awareness Month. The company has engaged in several initiatives throughout November and December aimed at raising awareness and providing support for those living with epilepsy and infantile spasms.

Community Engagement and Support

Rich Dudek, Vice President of Commercial Operations at Upsher-Smith, stated, "During National Epilepsy Awareness Month, we take this opportunity to celebrate the resilience of those living with epilepsy and their families." This proactive approach has seen the company participating in significant events like the 13th Annual Epilepsy Awareness Day at Disneyland, California, which gathered patients, caregivers, and medical professionals together.

Hosted by Sofie's Journey, a nonprofit organization aimed at improving education and support for families affected by epilepsy, this event has become one of the largest gatherings in the epilepsy community. Attendees had access to various educational sessions, expert panels, and interactive activities for children, along with the chance to connect and share experiences.

At the Disneyland event, Upsher-Smith showcased its product—VIGAFYDE® (vigabatrin) Oral Solution. This is a key medication for patients aged 1 month to 2 years who experience infantile spasms, and Upsher-Smith is committed to providing ongoing support through its comprehensive Promise of Support® Program, which offers resources for healthcare providers, patients, and caregivers.

Upcoming Awareness Initiatives

As December approaches, Upsher-Smith is set to sponsor the Eleventh Annual Infantile Spasms Awareness Week from December 1 to 7. This global initiative unites multiple organizations to promote awareness about the seriousness of infantile spasms—a rare but urgent form of epilepsy. The program focuses on educating healthcare professionals and families about recognizing signs, available treatments, and how to support affected families.

Moreover, the company will participate in the upcoming American Epilepsy Society Annual Meeting from December 5 to 9 in Atlanta, Georgia. This meeting provides a platform for Upsher-Smith to connect with clinicians and share information on its growing range of products focused on rare diseases. They will host a satellite symposium titled, “From Crisis to Care — Striving to Optimize Outcomes in Infantile Spasms,” featuring talks by leading experts in the field, highlighting the importance of early diagnosis and effective treatment strategies.

Expert Discussion and Education

The symposium on December 6, scheduled for 6:00 p.m. ET at the Georgia World Congress Center, aims to advance the clinical understanding of infantile spasms. Renowned specialists, including Dr. Sarah Weatherspoon from Le Bonheur Children's Hospital, Dr. Michael Chez from Sutter Neuroscience Institute, Dr. Sonam Bhalla from Children's Healthcare of Atlanta, and Dr. Muhammad Zafar from Duke University Hospital, will guide participants through discussions on the patient journey from diagnosis to treatment, emphasizing the necessity of individualized care plans and the role of caregivers.

To attend the symposium, interested parties can pre-register through the provided link.

Commitment to Pediatric Health

Upsher-Smith's continued advocacy for the epilepsy community emphasizes not just awareness but also the provision of critical resources necessary for improving patient outcomes. With a pledge towards the health of young children grappling with epilepsy, the company reassures its constituents of its unwavering support and commitment to raising awareness and providing educational resources.

For more insights on Upsher-Smith’s initiatives regarding rare pediatric diseases, please visit www.upsher-smith.com.

VIGAFYDE and Patient Safety

It's important to note that all vigabatrin products are governed by a Risk Evaluation and Mitigation Strategy (REMS) mandated by the FDA. This program ensures that both patients and healthcare providers are informed of the potential risks, including vision loss associated with the use of VIGAFYDE. Thus, healthcare providers must be enrolled in the Vigabatrin REMS to prescribe this treatment.

In conclusion, Upsher-Smith continues to play a significant role in enhancing the quality of life for families affected by epilepsy through awareness, education, and unwavering support.